June 28, 2017 7:13 AM ET


Company Overview of Acacia Pharma Limited

Company Overview

Acacia Pharma Limited, a specialty pharmaceutical company, discovers, develops, and commercializes pharmaceutical products in the United Kingdom and internationally. Its product pipeline includes BAREMSIS, which has completed Phase III clinical development for the prophylaxis and treatment of post-operative nausea and vomiting; APD403 that has completed two Phase II trials to prevent acute chemotherapy-induced nausea and vomiting; APD515, an oromucosal liquid formulation, which is in Phase II clinical study for reducing xerostomia in advanced cancer patients; and APD209, an oral and fixed dose combination formulation that has completed Phase IIa clinical study for the management of cancer ca...

Harston Mill


Cambridge,  CB22 7GG

United Kingdom

Founded in 2007

6 Employees


44 12 2387 5130


44 12 2387 5131

Key Executives for Acacia Pharma Limited

Co-Founder, Chief Executive Officer & Director
President, COO & Non-Executive Director
Age: 46
Founder and Chief Scientific Officer
CFO, Company Secretary & Director
Age: 58
Chief Medical Officer
Compensation as of Fiscal Year 2016.

Acacia Pharma Limited Key Developments

Acacia Pharma Limited Auditor Raises 'Going Concern' Doubt

Acacia Pharma Limited filed its Annual on Mar 09, 2017 for the period ending Dec 31, 2016. In this report its auditor, PricewaterhouseCoopers LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.

Acacia Pharma Group Ltd Announces Positive Results From its Fourth and Final Pivotal Trial of BAREMSIS™ for the Rescue Treatment of PONV

Acacia Pharma Group Ltd. announces positive results from its fourth and final pivotal Phase 3 study investigating BAREMSIS™ (amisulpride injection, formerly APD421) for the rescue treatment of patients who develop post-operative nausea & vomiting (PONV), despite having received prior antiemetic prophylaxis.   Acacia Pharma has now completed four pivotal Phase 3 studies of BAREMSIS successfully, all meeting their primary endpoint, and these will form the basis of the efficacy and safety package which the Company aims to submit to the US FDA as part of its New Drug Application (NDA) in first half of 2017. The Company will seek a broad and unique approval for BAREMSIS for the rescue treatment and prophylaxis of PONV, alone and in combination. PONV is distressing, can have a detrimental impact on surgical outcomes and significantly impede the post-operative recovery process. It can delay hospital discharge, lead to unanticipated readmissions increasing healthcare costs and give the patient a poor surgical experience. Better management of PONV can therefore decrease hospital costs and improve patient outcomes and satisfaction scores. Surgical patients at moderate or high risk of PONV are given prophylactic antiemetics prior to surgery, with standard-of-care based upon 5HT3 antagonists and corticosteroids. However, up to 40% of these patients develop PONV and must be treated with an antiemetic from a different mechanistic class. BAREMSIS is a dopamine antagonist antiemetic and offers anaesthetists a drug that is able to fulfil this important unmet medical need and better manage PONV. The Phase 3 rescue treatment trial compared two doses of BAREMSIS, a novel dopamine D2/D3 antagonist antiemetic, against placebo in patients with established nausea and/or vomiting after surgery, who had previously received prophylactic antiemetics. The double-blind study, the first ever major study to investigate rescue with a different class of antiemetic, took place in institutions in the USA, Canada, France and Germany and recruited 2,285 patients, of whom 705 (31%) went on to experience PONV and were randomised into the trial. The primary endpoint was the successful resolution of the episode of PONV (no recurrence of vomiting or requirement for further antiemetic rescue) in the 24-hour period after rescue treatment, termed a complete response. The optimum dose of BAREMSIS significantly improved the complete response rate when compared to placebo (p=0.003); the magnitude of effect was consistent with the Company's previous Phase 3 trial results.

Acacia Pharma Limited Auditor Raises 'Going Concern' Doubt

Acacia Pharma Limited filed its Annual on Sep 16, 2016 for the period ending Dec 31, 2015. In this report its auditor, PricewaterhouseCoopers LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.

Similar Private Companies By Industry

Company Name Region
Abbey Pharma Limited Europe
Absynth Biologics Limited Europe
Acacia Pharma Limited Europe
AccentBio Ltd. Europe
Aclar Limited Europe

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
The Advertising Council, Inc. United States
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Acacia Pharma Limited, please visit www.acaciapharma.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.